Abstract
Background: Ovarian reserve is affected by many factors and repeated ovulation is one of the factors thought to be responsible for the same. Clomiphene citrate (CC) is the most common drug used for ovulation induction in anovulation and also empirically for unexplained infertility. The study aimed to determine the ovarian reserve by day 3 follicle-stimulating hormone (FSH), anti-Mullerian hormone (AMH), and antral follicle count (AFC) in infertile women and also tried to determine ovarian response and any effect in ovarian reserve to increasing doses of CC. Materials and Methods: This prospective interventional study included 50 infertile women, who did not undergo ovulation induction for six or more cycles. Day 3 AFC, FSH, and AMH were determined in each cycle and treated with increasing doses of CC 50, 100, and 150 mg and monitored for follicular growth and ovulation by transvaginal scan (TVS) to know the ovarian response. Pregnancy rate and side-effects were monitored. Statistical Analysis: Correlation between the ovarian reserve tests was conducted with Pearson and Spearman correlation. Differences in parameters in three cycles were analyzed by repeated measures analysis of variance, statistical test (ANOVA). Ovarian reserve and response with increasing doses of CC were analyzed by logistic regression. Results: AFC and FSH emerged as better tests to predict ovarian reserve. A significant negative correlation was noted between AFC and FSH (r = −0.366; P = 0.0001). Positive correlations were obtained between AFC vs AMH and FSH vs AMH. Ovarian response significantly increased with increasing doses of CC. Ovarian reserve suffered a decrease with increasing doses of CC, but this did not reach significant levels. Conclusion: Although ovarian response increased with increasing doses of CC, there is a risk of decreased ovarian reserve with such therapy, and this finding should be confirmed by large sample size.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.